A Phase 2 interventional study of Daglutril in Hypertension, sponsored by Solvay Pharmaceuticals. Completed at 130 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-01-30.
Sponsored by Solvay Pharmaceuticals · Phase 2, Interventional, and Treatment
This study is to compare the efficacy and safety of increasing doses of SLV306 with amlodipine.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
Browse Hypertension studies →Solvay Pharmaceuticals is the lead sponsor of 84 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Showing the first 100 of 130 sites across 11 countries.
This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Solvay Pharmaceuticals